Advanced pancreatic cancer individuals now have access to new FDA-approved drug.

Onivyde, will be utilized as part of a combination program with a two-medication chemotherapy. It had been approved to treat patients with pancreatic cancer that progressed after treatment with a different chemotherapy. As part of the team of medical scientists who studied the effectiveness of MM-398 plus 5-FU and leucovorin drug combination, we are thrilled that the FDA offers approved the medication for use in sufferers throughout the nation, said Dr. Daniel D. Von Hoff, MD, FACP, global principal investigator of the NAPOLI-1 study, Chief Scientific Officer for HonorHealth Research Physician-In-Chief and Institute and Distinguished Professor in TGen.Kaiser Family Foundation. Copyright 2009 Advisory Board Firm and Kaiser Family Foundation. All rights reserved.. AUXILIO first one fourth net revenue increases 40 percent to $6.5 million AUXILIO, Inc. , the nation’s pioneer and leading Managed Print Services organization for health care, announced its financial results for the one fourth ended March 31, 2012. Flynn, cEO and president of AUXILIO, Inc. During the one fourth, we began implementing our MPS system for Catholic Wellness East , a multi-institutional health program, which represents the biggest contract signed inside our history. As a total result, our highly effective, risk-free MPS offering is currently gaining awareness among large-scale healthcare systems in the united states.